| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
Design Therapeutics, Inc.$15.19
+0.07 (+0.45%)
B 65Pipeline Score Undervalued Biotech · Clinical
Market Cap
685.15 M
EPS
-1.19
P/E Ratio
-
Value Trade
6.59 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
14.38 M
Operating CF
-16.43 M
Total Assets
230.44 M
Total Liabilities
12.39 M
Equity
218.05 M
D/E Ratio
12,345
-23.34 %
Week
-17.58 %
1 Month
7.87 %
3 Month
39.57 %
6 Month
-59.05 %
5 Year
-60.82 %
All Time
Cash Data
Cash Position
222.82 M
Monthly Burn
5.48 M
Runway
38.5 mo
Burn Trend
SEC Filing
Apr 28, 2026
Overview
Volume
836.76 K
52 Week Range
3.33 - 17.25
% held by Insiders
39.71 %
% held by Institutions
48.75 %
Enterprise Value
465.06 M
Total Shares
62.43 M
Short %
22.12 %
Float Shares
25.84 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Design Therapeutics, Inc.
114Total events
3Upcoming
20Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 3
Event history 111
Q3 2026
◆Topline ReadoutDT-216P2Clinical Data
Update on effect of DT-216P2 on endogenous frataxin levels after 12 weeks of dosing
Friedreich Ataxia (FA)source ↗
Q3 2026
◆Topline ReadoutDT-168Clinical Data
Data from Phase 2 biomarker trial of DT-168 in FECD
Fuchs Endothelial Corneal Dystrophy (FECD)source ↗
Jun 30, 2026
▲First Patient DosedDT-818Trial
Initiation of patient dosing in Phase 1 MAD trial of DT-818 for DM1
myotonic dystrophy type-1source ↗
Jun 4, 2026
◆Oral PresentationPresentation
Management to participate in fireside chat at 2026 Jefferies Global Healthcare Conference
May 18, 2026
◆Oral PresentationDT-216P2Presentation
Investor webcast to review data from RESTORE-FA trial of DT-216P2
Friedreich's ataxiasource ↗
Feb 18, 2026
2026
●Trial InitiationDT-216P2Trial
RESTORE-FA multiple ascending dose trial ongoing
Friedreich ataxiasource ↗
2026
◆Topline ReadoutDT-216P2Clinical Data
MAD trial data including FXN expression after 12 weeks
Friedreich ataxiasource ↗
Q1 2026
◆First Patient DosedDT-818Trial
First patient dosed in Phase 1 MAD trial of DT-818 in DM1
Myotonic Dystrophy Type-1 (DM1)source ↗
Drug Pipeline Intelligence
B65
Pipeline Score $4.0B
Pipeline ValueUndervalued
Valuation Signal19
Drugs Scored5.8x
rNPV / MCap Top 92%
Micro Cap (rank 74 of 911)
Percentile RankDesign Therapeutics, Inc. holds a solid B-grade pipeline (65/100), with $9.9B risk-adjusted pipeline value, led by Influenza vaccine in Infection in Solid Organ Transplant Recipients (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza vaccine Monoclonal antibody | Infection in Solid Organ Transplant Recipients | Phase 3 | NCT01761435 | 57% | $2.1B | COMPLETED | 499 | - | - | Jan 1, 2014 | - | May 1, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DT-216P2 | Friedreich Ataxia | Phase 1/2 | 2025-08-07 | Early human PK data for DT-216P2 demonstrate the consistency of human plasma exposure profiles with NHP data across both IV and subcutaneous routes. Read More | Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results Read More | |
DT-216P2 | Friedreich Ataxia | Phase 1/2 | 2025-08-07 | Early human PK data for DT-216P2 demonstrate the consistency of human plasma exposure profiles with NHP data across both IV and subcutaneous routes. Read More | Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results Read More | |
DT-216P2 | Friedreich Ataxia | Phase 1/2 | 2025-08-07 | Early human PK data for DT-216P2 demonstrate the consistency of human plasma exposure profiles with NHP data across both IV and subcutaneous routes. Read More | Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DSGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DSGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DSGNDesign Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics has commenced patient dosing in a Phase 1 trial for DT-818, aimed at treating myotonic dystrophy type-1 (DM1). This trial will evaluate the safety and pharmacokinetics of the drug, which targets the mutant DMPK allele responsible for DM1. The company anticipates reporting results in 2027, marking a crucial step in addressing this genetic disorder.
Read more →DSGNDesign Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Design Therapeutics, Inc. will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The event will showcase the company's innovative GeneTAC platform, which targets genetic diseases. A live webcast will be available, and the session will be archived for 30 days. This participation underscores the company's focus on advancing its clinical-stage programs.
Read more →DSGN▼ -25.5%on this news
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
Design Therapeutics will present data from its Phase 1/2 RESTORE-FA trial of DT-216P2 for Friedreich's ataxia on May 18, 2026. The company is focused on developing therapies for serious genetic diseases using its GeneTAC platform. The webcast will be accessible to investors and archived for later viewing.
Read more →DSGN▲ +23.3%on this news
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Design Therapeutics announced its first quarter 2026 financial results, highlighting a cash position of $222.8 million and ongoing clinical trials, particularly the RESTORE-FA trial for DT-216P2 aimed at treating Friedreich ataxia. The company also appointed Dr. David Shapiro to its Board of Directors to strengthen its clinical and regulatory capabilities. Despite positive developments, the company acknowledged potential risks associated with clinical trials.
Read more →DSGNDesign Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the Firs
Design Therapeutics reported its fourth-quarter and full-year financial results for 2025, highlighting ongoing clinical trials for its GeneTAC portfolio, including DT-216P2, DT-168, and DT-818. The company has a robust cash position of $219.8 million, which supports its operations through at least 2029. Anticipated data readouts from these trials are expected in the second half of 2026, reflecting significant progress in their clinical development. However, Design faces challenges such as a substantial net loss and dependencies on upcoming clinical results.
Read more →DSGNDesign Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, a clinical-stage biotechnology company, has announced its participation in upcoming investor conferences. The company focuses on developing GeneTAC therapies for serious degenerative genetic diseases, including Friedreich ataxia and myotonic dystrophy type-1. Live webcasts of the presentations will be available on their website, archived for 30 days.
Read more →DSGNDesign Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
Design Therapeutics announced plans to initiate patient dosing of DT-818 for Myotonic Dystrophy Type-1 (DM1) in the first half of 2026. The company reported strong financial results for Q3 2025, with $206 million in cash to support its pipeline. DT-818 is positioned as a potentially best-in-disease treatment, while trials for other candidates continue to progress.
Read more →DSGNDesign Therapeutics Appoints Justin Gover to Board of Directors
Design Therapeutics has appointed Justin Gover to its Board of Directors, effective immediately. Gover brings over 25 years of biotechnology experience, notably as the founding CEO of GW Pharmaceuticals. This transition follows the departure of Dr. Arsani William, who played a crucial role in the company's growth. Gover's expertise is expected to support the advancement of Design's clinical pipeline.
Read more →DSGNDesign Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
Design Therapeutics, Inc. will participate in the 2025 Cantor Global Healthcare Conference on September 4, 2025. The event will feature a fireside chat with management, which will be available via live webcast. The company is focused on developing GeneTAC therapies for serious genetic diseases, including Friedreich ataxia and Fuchs endothelial corneal dystrophy.
Read more →DSGN▲ +7.8%on this news· ran to +37% by day 3
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
Design Therapeutics reported significant advancements in its GeneTAC® programs, highlighting early human pharmacokinetics data for DT-216P2 and the initiation of a Phase 2 biomarker study for DT-168. The company maintains a strong financial position with $216.3 million in cash and securities to support ongoing development. However, potential FDA clinical holds could impact timelines for U.S. trials.
Read more →DSGNDesign Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
Design Therapeutics has initiated dosing of the first patient in its RESTORE-FA Phase 1/2 trial for Friedreich ataxia with DT-216P2. Initial data from a prior trial indicates a favorable safety profile. However, the company faces a clinical hold from the FDA on its IND application for U.S. sites due to nonclinical deficiencies. The trial is currently open for enrollment in Australia, with data expected in 2026.
Read more →DSGNDesign Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
Design Therapeutics, a clinical-stage biotechnology company, will present at the 2025 Jefferies Global Healthcare Conference on June 4, 2025. The presentation will focus on their innovative GeneTAC platform, which aims to treat serious degenerative genetic diseases. The event will be available via live webcast and archived for later viewing.
Read more →DSGNDesign Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
Design Therapeutics, a clinical-stage biotech firm, will participate in the 2025 RBC Capital Markets Healthcare Conference on May 20, 2025. The event will feature a fireside chat with management at 8:00 a.m. ET in New York. The company focuses on developing GeneTAC therapies for genetic diseases, including Friedreich ataxia and Fuchs endothelial corneal dystrophy.
Read more →DSGN▼ -8.3%on this news
Design Therapeutics Highlights Momentum Across Lead GeneTAC Programs and Reports First Quarter 2025 Financial Results Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Fa
Design Therapeutics, a biotechnology firm focused on genetic diseases, announced progress in its GeneTAC programs alongside their financial results for Q1 2025. The company reported promising Phase 1 data for its therapy DT-168 targeting Fuchs endothelial corneal dystrophy (FECD) and is advancing plans for a Phase 2 trial. Additionally, they are conducting a Phase 1 clinical trial for DT-216P2 aimed at Friedreich Ataxia (FA). The company maintains a strong cash position to support its operations through multiple trial phases over the coming years.
Read more →DSGNDesign Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
Design Therapeutics announced positive Phase 1 trial results for DT-168, an eye drop treatment targeting the mutant TCF4 gene linked to Fuchs endothelial corneal dystrophy (FECD). The company plans to initiate a Phase 2 biomarker trial later in 2025, aiming to evaluate safety and corneal endothelium biomarkers in FECD patients. This could lead to the first disease-modifying therapy for this condition.
Read more →DSGN▲ +10.3%on this news
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
Design Therapeutics will present Phase 1 data for its DT-168 program targeting Fuchs endothelial corneal dystrophy at Eyecelerator @ Park City 2025. The presentation will cover safety findings from trials in healthy volunteers and future plans for Phase 2 development. DT-168 aims to address the genetic cause of FECD, which currently lacks effective treatments.
Read more →DSGNDesign Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Fourth Quarter and Full Year 2024 Financial Results Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedr
Design Therapeutics has announced significant advancements in its GeneTAC programs, including the initiation of a Phase 1 trial for DT-216P2 targeting Friedreich Ataxia. The company successfully completed a Phase 1 trial involving DT-168 and expects to report data for it in the first half of 2025. Additionally, Design is well-capitalized with $245.5 million in cash reserves to support continued clinical development across its pipeline, with notable milestones anticipated in 2025 for programs in both FA and myotonic dystrophy type-1.
Read more →DSGNDesign Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC TM Portfolio Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the Fi
Design Therapeutics reported its third quarter 2024 financial results, highlighting the anticipation of significant milestones in its GeneTAC portfolio. The company has initiated Phase 1 trials for Fuchs Endothelial Corneal Dystrophy and is on track to start a Phase 1 trial for Friedreich Ataxia in the first half of 2025. Despite a net loss of $13.0 million for the quarter, the firm maintains a healthy cash position of $254.1 million to support future operations and development activities.
Read more →DSGNDesign Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC TM Portfolio Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Ad
Design Therapeutics reported its second quarter 2024 financial results, showing steady progress in its GeneTAC candidate programs, particularly for Friedreich Ataxia and Fuchs Endothelial Corneal Dystrophy. The company plans to initiate patient trials for its lead candidate DT-216P2 in 2025, with strong financial backing of $261 million expected to fund its operations into 2029. The announcement highlights anticipated milestones as well as ongoing development for programs in Huntington's Disease and Myotonic Dystrophy Type-1. Net losses for the quarter were reported at $11.8 million, raising concerns about future economic sustainability.
Read more →DSGNDesign Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Devel
Design Therapeutics reported its first quarter 2024 financial results, highlighting key milestones and advancements in its treatment pipeline. The company is poised to start clinical trials for DT-216P2, a new drug for Friedreich Ataxia, while also progressing with observational studies in Fuchs Endothelial Corneal Dystrophy. With a healthy cash position of $270.7 million, Design is well-equipped to support its multi-year operational plans and development of its GeneTAC programs. However, the company also faces significant risks including a reported net loss and uncertainties regarding future clinical developments.
Read more →DSGNDesign Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokine
Design Therapeutics provided an update on its GeneTAC platform and disclosed its 2023 financial results. The company announced the development of a new drug product, DT-216P2, for Friedreich Ataxia, which is positioned for clinical trials starting in 2025. Additionally, the FDA cleared the IND for DT-168, aimed at treating Fuchs Endothelial Corneal Dystrophy, with plans for a Phase 1 trial in 2024. Lastly, Design introduced a new program targeting Huntington's Disease and reported a solid cash position to support its pipeline.
Read more →DSGNDesign Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024 Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Tu
Design Therapeutics has reported its third quarter 2023 financial results, showcasing a solid cash position of approximately $290 million, which will support operations through 2028. The company has appointed seasoned biotech executive Pratik Shah as the new CEO to lead its strategic realignment towards long-term growth. Key plans for early 2024 include a comprehensive update on its corporate strategy and anticipated milestones across its pipeline of GeneTAC small molecules, particularly those targeting serious genetic diseases. Recent clinical data provides proof-of-concept for its lead candidate, DT-216, in treating Friedreich ataxia, hinting at a promising future for the company's therapeutic approaches.
Read more →DSGNDesign Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mR
Design Therapeutics has provided an update on its clinical pipeline, highlighting promising initial results from the Phase 1 trial of DT-216 for Friedreich ataxia, which showed a significant increase in FXN mRNA levels. The company plans to resume a Phase 1 clinical study with an improved formulation in 2024 and anticipates reporting further data in 2025. Additionally, Design is on track to submit an IND for its DT-168 eye drop treatment in the second half of 2023. The company maintains a strong financial position, expecting to support operations through 2026.
Read more →DSGNDesign Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Expected in the Third Quarter of 2023
Design Therapeutics has provided updates on its clinical and research pipeline while reporting its first quarter 2023 financial results. Significant milestones include the upcoming initial data from a Phase 1 multiple-ascending dose trial of DT-216 for Friedreich ataxia expected in Q3 2023, along with planned IND submissions for additional treatments later this year. The company remains financially stable with $315.4 million in cash, which is projected to cover operations until 2025. Overall, Design is focused on catalyzing advancements in treating serious genetic diseases.
Read more →DSGNDesign Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Ongoing with Data Expected Mid-Year C
Design Therapeutics has reported notable progress in its pipeline, particularly with the ongoing Phase 1 multiple-ascending dose trial of DT-216 for Friedreich ataxia, expected to yield data by mid-2023. The company is also advancing several other GeneTAC small molecule programs, including DT-168 for Fuchs endothelial corneal dystrophy. Financially, Design holds $330 million, allowing them to fund operations through 2025. Overall, the company aims to bring two additional programs into clinical development in the next two years.
Read more →DSGNDesign Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022 Dosing Initiated in the Multi
Read more →DSGNDesign Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022 Strong Financial Pos
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022 Strong Financial Position with $359.4 Million in Cash and Securities to Suppor
Read more →DSGNDesign Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results Clinical Execution of Lead GeneTAC TM Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of
Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results Clinical Execution of Lead GeneTACTM Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of Friedreich Ataxia Robust Research Pipeline of GeneTACTM Ca
Read more →DSGNDesign Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results Phase 1 Trial of DT-216, a Novel FA GeneTAC TM Molecule, in Patients with Friedreich Ataxia On Track to B
Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results Phase 1 Trial of DT-216, a Novel FA GeneTACTM Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel
Read more →DSGNDesign Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results Clinical Initiation of Lead GeneTAC TM Program for Friedreich Ataxia On-track for the First Half of 2022 Carlsbad, CA
Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results Clinical Initiation of Lead GeneTACTM Program for Friedreich Ataxia On-track for the First Half of 2022 Carlsbad, CA, Nov. 9, 2021 Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company deve
Read more →DSGNDesign Therapeutics Reports GeneTAC Portfolio Progress and Second Quarter 2021 Results Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022 L
Design Therapeutics Reports GeneTAC Portfolio Progress and Second Quarter 2021 Results Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022 Leadership Team Strengthened with Appointment of Elizabeth
Read more →DSGNDesign Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results Successful $276 Million IPO Completed to Advance GeneTAC TM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1
Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results Successful $276 Million IPO Completed to Advance GeneTACTM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development Company On-track to Initiate P
Read more →DSGNDesign Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Carlsbad, CA
Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Carlsbad, CA, March 30, 2021 Design Therapeutics, Inc. (Nasdaq: DSGN) ( Design ), a biotechnology company developing a platform of gene targe
Read more →Competitive Position
How DSGN ranks across every disease it competes inCompetitive Position is a premium feature
See how DSGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial